Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pan Afr Med J ; 26: 58, 2017.
Article in French | MEDLINE | ID: mdl-28451035

ABSTRACT

The most common primary sites for bone metastases in men are lung, prostate, kidney, thyroid or bladder. Colorectal origin is rare. Few studies have described this type of metastases; the axial skeleton or the pelvis are the most common metastasis locations. Craniofacial location is exceptional. We here report the case of a 38 years old man treated for metastatic rectal cancer metastasized to temporal bone. He initially had undergone surgical procedure for low anterior resection, tumor was classified as pT3N0M0; 24 months after the patient had left exophthalmos revealing a temporal tumoral process. Evolution and context favoured metastasis. In conclusion, this study reporting an exceptional case of craniofacial bone metastasis from multi-metastatic colorectal cancer will enrich the scarce data reported in the literature related to bone metastases from primary colorectal cancer.


Subject(s)
Bone Neoplasms/secondary , Rectal Neoplasms/pathology , Skull Neoplasms/secondary , Temporal Bone/pathology , Adenocarcinoma/pathology , Adult , Bone Neoplasms/diagnosis , Bone Neoplasms/pathology , Humans , Male , Skull Neoplasms/diagnosis , Skull Neoplasms/pathology
2.
Pan Afr Med J ; 25: 205, 2016.
Article in French | MEDLINE | ID: mdl-28292162

ABSTRACT

Primitive large cell neuroendocrine tumor of the breast is an extremely rare entity. Less than ten cases have been reported in the literature. We report a new case of a 61-year old male patient presenting with locally advanced tumor of the right breast, immediately metastasized to the lungs and pleura, staged cT4bN1M1. The patient received eight cycles of Docetaxel-based chemotherapy every 21 days, with a good clinical and radiological response (>50%), followed by adjuvant tamoxifen with disease stabilization for 18 months. Immunohistochemistry is still essential to determine the neuroendocrine nature of this tumor. Treatment is not well codified due to the rarity of this type of cancer.


Subject(s)
Breast Neoplasms, Male/pathology , Carcinoma, Neuroendocrine/pathology , Lung Neoplasms/pathology , Pleural Neoplasms/pathology , Antineoplastic Agents/therapeutic use , Breast Neoplasms, Male/drug therapy , Carcinoma, Neuroendocrine/drug therapy , Chemotherapy, Adjuvant/methods , Docetaxel , Humans , Immunohistochemistry , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Male , Middle Aged , Neoplasm Staging , Pleural Neoplasms/drug therapy , Pleural Neoplasms/secondary , Tamoxifen/administration & dosage , Taxoids/administration & dosage , Taxoids/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...